Longsworth Todd Christopher 4
4 · NovoCure Ltd · Filed Mar 7, 2022
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Longsworth Todd Christopher
General Counsel
Transactions
- Sale
Ordinary Shares
2022-03-03$74.50/sh−1,094$81,501→ 66,774 total - Sale
Ordinary Shares
2022-03-04$70.41/sh−1,973$138,913→ 64,801 total - Award
Options to Buy Ordinary Shares
2022-03-03$80.59/sh+6,106$492,083→ 6,106 totalExercise: $80.59From: 2023-03-01Exp: 2032-02-29→ Ordinary Shares (6,106 underlying)
Footnotes (2)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.